Abstract
The main goal of the therapy of inflammatory bowel diseases is the induction and maintenance of disease remission. Whereas the standard medical approach is guided by the clinical symptoms and concurrent therapy of the patients (‘step-up’ approach), a new evolving concept for patients with Crohn’s disease is trying to modify the disease course by treating intestinal inflammation early and very aggressively with anti-TNF therapy and immunosuppressive agents, such as azathioprine (‘top-down’ approach). This review discusses the background of this new approach in Crohn’s disease and places the first available clinical results of ‘top-down’ therapy into perspective with available data on potential adverse effects, the natural course and the therapeutic goal of mucosal healing in Crohn’s disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
